BioCentury

8:00 AM GMT, Feb 2, 2015
This article and the information contained in BioCentury's publications and services are solely for your own personal, non-transferable licensed use and cannot be shared with any other individuals. For information about adding subscribers to your account or obtaining article reprints, please contact support@biocentury.com.
Emerging Company Profile

Battling blood

Global Blood Therapeutics Inc. is developing a small molecule that allosterically binds to hemoglobin and could be a disease-modifying treatment for sickle cell disease.

The product could provide an alternative to the only cure - bone marrow transplant - as well as to Phase III candidates that are seeking to reduce the duration or frequency of vaso-occlusive crisis. These acute pain crises are caused when sickled red blood cells block vessels, and usually require hospitalization and narcotics.

"We're not trying to treat crisis. We're trying to

Read the full 877 word article

This article and the information contained in BioCentury's publications and services are solely for your own personal, non-transferable licensed use and cannot be shared with any other individuals. For information about adding subscribers to your account or obtaining article reprints, please contact support@biocentury.com.